T. Rowe Price Associates
GWPH

T. Rowe Price Associates’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History

T. Rowe Price Associates’s Portfolio GWPH Stock Details GWPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-508,872
Closed -$58.7M – 2890
2020
Q4 		$58.7M Buy
508,872
+33,356
+7% +$3.74M 0.01% 904
2020
Q3 		$46.3M Sell
475,516
-105,180
-18% -$12.1M 0.01% 897
2020
Q2 		$71.3M Buy
580,696
+86,085
+17% +$9.77M 0.01% 733
2020
Q1 		$43.3M Sell
494,611
-225,289
-31% -$23.9M 0.01% 829
2019
Q4 		$75.3M Buy
719,900
+290,939
+68% +$32.6M 0.01% 762
2019
Q3 		$49.3M Sell
428,961
-16,597
-4% -$2.52M 0.01% 878
2019
Q2 		$76.8M Sell
445,558
-27,550
-6% -$4.77M 0.01% 723
2019
Q1 		$79.8M Sell
473,108
-28,469
-6% -$4.24M 0.01% 703
2018
Q4 		$48.8M Sell
501,577
-249,139
-33% -$32.7M 0.01% 831
2018
Q3 		$130M Sell
750,716
-113,133
-13% -$16.3M 0.02% 602
2018
Q2 		$121M Buy
863,849
+184,268
+27% +$26.2M 0.02% 610
2018
Q1 		$76.6M Sell
679,581
-317,419
-32% -$39.9M 0.01% 716
2017
Q4 		$132M Buy
997,000
+36,874
+4% +$4.33M 0.02% 563
2017
Q3 		$97.4M Buy
960,126
+146,824
+18% +$15.7M 0.02% 634
2017
Q2 		$81.5M Buy
813,302
+79,618
+11% +$8.57M 0.01% 665
2017
Q1 		$88.7M Buy
733,684
+266,790
+57% +$32.7M 0.02% 628
2016
Q4 		$52.2M Sell
466,894
-74,720
-14% -$8.99M 0.01% 796
2016
Q3 		$71.9M Buy
541,614
+379,440
+234% +$36.3M 0.01% 679
2016
Q2 		$14.8M Buy
+162,174
New +$13.7M ﹤0.01% 1190
2014
Q3 		– Sell
-145,724
Closed -$15.6M – 2578
2014
Q2 		$15.6M Sell
145,724
-153,115
-51% -$10.6M ﹤0.01% 1187
2014
Q1 		$17.7M Buy
298,839
+153,709
+106% +$9.14M ﹤0.01% 1147
2013
Q4 		$6.03M Hold
145,130
– – ﹤0.01% 1401
2013
Q3 		$2.52M Hold
145,130
– – ﹤0.01% 1510
2013
Q2 		$1.26M Buy
+145,130
New +$1.28M ﹤0.01% 1604

Other funds holding GWPH

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's GWPH Position: Q1 2021 in Review

T. Rowe Price Associates sold out of GW Pharmaceuticals Plc American Depositary Shares (GWPH) in Q1 2021, closing a stake of 508,872 shares — an estimated $58.7M sold.

T. Rowe Price Associates first reported a position in GWPH in Q2 2013 and held it in 24 quarters. The position peaked at $132M in Q4 2017. 297 funds tracked by Wall St. Rank hold GWPH as of Q1 2021.

  • T. Rowe Price Associates reported no remaining GW Pharmaceuticals Plc American Depositary Shares position as of Q1 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 508,872 GW Pharmaceuticals Plc American Depositary Shares shares in Q1 2021, an estimated $58.7M.
  • T. Rowe Price Associates first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q2 2013 and held it in 24 quarters.
  • T. Rowe Price Associates's GW Pharmaceuticals Plc American Depositary Shares position peaked at $132M in Q4 2017.
  • 297 funds tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q1 2021.

Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.